Skip to main content
. 2015 Aug 3;108(1):4–20. doi: 10.1093/cvr/cvv205

Figure 1.

Figure 1

Strategies to increase cardiac-specific gene transfer using AAV vectors using naturally occurring AAV serotypes, AAV capsid engineering, or directed molecular evolution and in vivo selection of cardiotropic AAV variants (see text for details). The relative cardiac transduction efficiency of the naturally occurring AAV serotypes (AAV2, AAV1, AAV6, AAV8, and AAV9) based on preclinical murine studies is shown schematically.